In the US, Fluoxymesterone (fluoxymesterone systemic) is a member of the following drug classes: androgens and anabolic steroids, hormones/antineoplastics and is used to treat Breast Cancer, Breast Cancer - Palliative, Delayed Puberty - Male, Hypogonadism - Male and Postmenopausal Symptoms.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-metyl-, (11β,17β)-
- Fluoxymesteronum (Latin)
- Fluoxymesteron (German)
- Fluoxymestérone (French)
- Fluoximesterona (Spanish)
- Fluoxymesterone (OS: BAN, JAN, DCIT)
- Fluoxymestérone (OS: DCF)
- Androfluorene (IS)
- Fluoxymesterone (PH: BP 1988, JP XVI, USP 38)
Upsher-Smith, United States
Ta Fong, Taiwan
Yuan Chou, Taiwan
- Fluoxymesterone Chen Ho
Chen Ho, Taiwan
New Chemical, Taiwan
Long Der, Taiwan
- Ton Lin
Chin Teng, Taiwan
|BAN||British Approved Name|
|DCF||Dénomination Commune Française|
|DCIT||Denominazione Comune Italiana|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.